Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? Academic Article uri icon

Overview

abstract

  • Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity.

publication date

  • June 1, 2002

Research

keywords

  • Antimetabolites, Antineoplastic
  • Central Nervous System Neoplasms
  • Lymphoma
  • Methotrexate

Identity

Scopus Document Identifier

  • 0036063821

Digital Object Identifier (DOI)

  • 10.1023/a:1016077907952

PubMed ID

  • 12164690

Additional Document Info

volume

  • 58

issue

  • 2